CRP and COVID-19: Since the beginning of the COVID-19 pandemic, these drugs have been used due to their ability to improve glycemic control and decrease the expression of inflammatory cytokines, including the Tumor Necrosis Factor (TNF), Interleukin -4, interleukin 1B, and C-Reactive Protein (CRP) [48], thus reducing COVID-19-induced inflammation and lung damage [48].